Preclinical study of a fully human anti-PD-L1 antibody as a theranostic agent for cancer immunotherapy

M Xu, Y Han, G Liu, Y Xu, D Duan, H Liu… - Molecular …, 2018 - ACS Publications
Recently, inhibiting the PD-1/PD-L1 checkpoint pathway utilizing anti-PD-1 or anti-PD-L1
antibodies has achieved great clinical success in cancer treatment. However, anti-PD-1 …
被引用次数：42 相关文章

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy

M Xu, Y Han, G Liu, Y Xu, D Duan… - Molecular …, 2018 - pubmed.ncbi.nlm.nih.gov
Recently, inhibiting the PD-1/PD-L1 checkpoint pathway utilizing anti-PD-1 or anti-PD-L1
antibodies has achieved great clinical success in cancer treatment. However, anti-PD-1 …

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.

M Xu, Y Han, G Liu, Y Xu, D Duan, H Liu… - Molecular …, 2018 - europepmc.org
Recently, inhibiting the PD-1/PD-L1 checkpoint pathway utilizing anti-PD-1 or anti-PD-L1
antibodies has achieved great clinical success in cancer treatment. However, anti-PD-1 …

[引用][C] Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy

M Xu, Y Han, G Liu, Y Xu, D Duan, H Liu, F Du… - Molecular …, 2018 - cir.nii.ac.jp
Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer
Immunotherapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …